{
    "Trade/Device Name(s)": [
        "Diazyme Apolipoprotein B Assay"
    ],
    "Submitter Information": "Diazyme Laboratories",
    "510(k) Number": "K073488",
    "Predicate Device Reference 510(k) Number(s)": [
        "K993354"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MSJ",
        "JIT",
        "JJX"
    ],
    "Summary Letter Date": "February 21, 2008",
    "Summary Letter Received Date": "February 22, 2008",
    "Submission Date": "September 24, 2007",
    "Regulation Number(s)": [
        "21CFR862.1475",
        "21CFR862.1150",
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Lipoprotein test system",
        "Alpha-1-lipoprotein Immunological Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Apolipoprotein B"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetric assay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Diazyme Apolipoprotein B Assay, a quantitative immunoturbidimetric assay for serum apolipoprotein B measurement to aid coronary artery disease risk assessment.",
    "Indications for Use Summary": "Intended for quantitative determination of apolipoprotein B (apo B) in serum as an aid for assessing risk of coronary artery disease; for in vitro diagnostic use.",
    "fda_folder": "Clinical Chemistry"
}